| Literature DB >> 28958995 |
Yuan Huang1, Peng Quan2, Yong-Wei Wang3, Dong-Sheng Zhang4, Ming-Wan Zhang3, Rui Li3, Nan Jiang3.
Abstract
Ursolic acid (UA) and oleanolic acid (OA) are insoluble drugs. The objective of this study was to encapsulate them into β-cyclodextrin (β-CD) and compare the solubility and intermolecular force of β-CD with the two isomeric triterpenic acids. The host-guest interaction was explored in liquid and solid state by ultraviolet-visible absorption,1 H NMR, phase solubility analysis, and differential scanning calorimetry, X-ray powder diffractometry, and molecular modeling studies. Both experimental and theoretical studies revealed that β-CD formed 1: 1 water soluble inclusion complexes and the complexation process was naturally favorable. In addition, the overall results suggested that ring E with a carboxyl group of the drug was encapsulated into the hydrophobic CD nanocavity. Therefore, a clear different inclusion behavior was observed, and UA exhibited better affinity to β-CD compared with OA in various media due to little steric interference, which was beneficial to form stable inclusion complex with β-CD and increase its water solubility effectively.Entities:
Year: 2017 PMID: 28958995 PMCID: PMC5706432 DOI: 10.7555/JBR.31.20160073
Source DB: PubMed Journal: J Biomed Res ISSN: 1674-8301
Factor and level of orthogonal experiment design.
| Level | Factor | |||
|---|---|---|---|---|
| A(Molar ratio) | B(h) | C(rpm) | D(°C) | |
| 1 | 1:1 | 4 | 200 | 20 |
| 2 | 1:5 | 6 | 300 | 30 |
| 3 | 1:10 | 8 | 400 | 40 |
The parameters of OA-β-CD and UA-β-CD in buffer solutions (pH=9) at various temperatures. (n=3)
| OA-β-CD | UA-β-CD | |||||
|---|---|---|---|---|---|---|
| 298K | 308K | 318K | 298K | 308K | 318K | |
| CE(%,W/W) | 0.142 | 0.198 | 0.209 | 0.200 | 0.209 | 0.227 |
| K So(L·mol-1) | 7878 | 7770 | 7702 | 25189 | 20177 | 14372 |
| K Sint(L·mol-1) | 208 | 318 | 328 | − a | 2517 | 3606 |
| ΔG(KJ·mol -1) | −22.23 | −22.94 | −23.66 | −25.11 | −25.38 | −25.31 |
| ΔH(KJ·mol -1) | −891 | −885 | −891 | −22073 | −22244 | −22066 |
| ΔS(J·mol -1·K-1) | 71.60 | 10.46 |
Data are the mean of three determinations.
KSo: The stability constant calculated from Eq. (2) using S0; KSint: The stability constant calculated from Eq. (2) using S int.-a: Sint<0.
Results from L9 (34) orthogonal test for optimization of OA-β-CD complexes preparation.
| Group | A | B | C | D | DL (%, W/W) |
|---|---|---|---|---|---|
| 1 | 1:1 | 4 | 200 | 20 | 0.40 |
| 2 | 1:1 | 6 | 300 | 30 | 1.02 |
| 3 | 1:1 | 8 | 400 | 40 | 1.92 |
| 4 | 1:5 | 4 | 300 | 40 | 0.84 |
| 5 | 1:5 | 6 | 400 | 20 | 1.70 |
| 6 | 1:5 | 8 | 200 | 30 | 0.24 |
| 7 | 1:10 | 4 | 400 | 30 | 0.95 |
| 8 | 1:10 | 6 | 200 | 40 | 0.43 |
| 9 | 1:10 | 8 | 300 | 20 | 0.75 |
| K 1 | 3.33 | 2.19 | 1.07 | 2.85 | |
| K 2 | 2.79 | 3.15 | 2.62 | 2.21 | |
| K 3 | 2.13 | 2.91 | 4.56 | 3.19 | |
| R | 1.21 | 0.96 | 3.49 | 0.98 |
Results from L9 (34) orthogonal test for optimization of UA-β-CD complexes preparation.
| Group | A | B | C | D | Drug loading dosage (%, W/W) |
|---|---|---|---|---|---|
| 1 | 1:1 | 4 | 200 | 20 | 0.14 |
| 2 | 1:1 | 6 | 300 | 30 | 0.19 |
| 3 | 1:1 | 8 | 400 | 40 | 0.11 |
| 4 | 1:5 | 4 | 300 | 40 | 0.08 |
| 5 | 1:5 | 6 | 400 | 20 | 0.17 |
| 6 | 1:5 | 8 | 200 | 30 | 0.10 |
| 7 | 1:10 | 4 | 400 | 30 | 0.13 |
| 8 | 1:10 | 6 | 200 | 40 | 0.06 |
| 9 | 1:10 | 8 | 300 | 20 | 0.16 |
| K 1 | 0.44 | 0.35 | 0.30 | 0.47 | |
| K 2 | 0.34 | 0.42 | 0.43 | 0.42 | |
| K 3 | 0.35 | 0.37 | 0.41 | 0.25 | |
| R | 0.10 | 0.07 | 0.13 | 0.22 |